[go: up one dir, main page]

PE20071116A1 - Compuestos de heteroarilo biciclicos como inhibidores de pde10 - Google Patents

Compuestos de heteroarilo biciclicos como inhibidores de pde10

Info

Publication number
PE20071116A1
PE20071116A1 PE2007000001A PE2007000001A PE20071116A1 PE 20071116 A1 PE20071116 A1 PE 20071116A1 PE 2007000001 A PE2007000001 A PE 2007000001A PE 2007000001 A PE2007000001 A PE 2007000001A PE 20071116 A1 PE20071116 A1 PE 20071116A1
Authority
PE
Peru
Prior art keywords
alkyl
bicycle
heteroaryl
benzoimidazole
pyridin
Prior art date
Application number
PE2007000001A
Other languages
English (en)
Inventor
Christopher John Helal
Patrick Robert Verhoest
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20071116A1 publication Critical patent/PE20071116A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROARILO BICICLICO DE FORMULA (I), DONDE HET1 SE SELECCIONA DE HETEROARILO MONOCICLICO Y UN HETEROARILO BICICLICO, DONDE DICHO HET1 ESTA OPCIONALMENTE SUSTITUIDO CON POR LO MENOS UN R4; HET2 ES UN HETEROARILO MONOCICLICO OPCIONALMENTE SUSTITUIDO CON R5; HET3 ES UN HETEROARILO BICICLICO DE 8 O 9 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R6; R1 ES HALOGENO, OH, CIANO, ALQUILO C1-C8, ENTRE OTROS; B1 Y B2 SON CARBONO O NITROGENO; B3 ES CARBONO; B4 ES NITROGENO; X Y X1 SON OXIGENO, AZUFRE O C(R2)2; R4 ES H, ALQUILO C1-C8, CIANO, OH, ENTRE OTROS; R5 ES HALOGENO, OH, ALQUENILO C2-C8, ENTRE OTROS; R6 ES ALQUILO C1-C8, ALQUENILO C2-C8, OH, ENTRE OTROS; R2 ES ALQUILO C1-C8, H, ALQUENILO C2-C8, ENTRE OTROS; p ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: 1-METIL-2-[4-(4-PIRIDIN-4-IL-1H-PIRAZOL-3-IL)-FENOXIMETIL]-1H-BENZOIMIDAZOL, 2-[4-(1-ETIL-4-PIRIDIN-4-IL-1H-PIRAZOL-3-IL)-FENOXIMETIL]-1-METIL-1H-BENZOIMIDAZOL, 1-{3-[4-(1-METIL-1H-BENZOIMIDAZOL-2-IL-METOXI)-FENIL]-4-PIRIDIN-4-IL-PIRAZOL-1-IL}-PROPAN-2-OL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA (PDE), PREFERIBLEMENTE PDE-10 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS NEURODEGENERATIVOS, PSIQUIATRICOS, ENTRE OTROS
PE2007000001A 2006-01-05 2007-01-03 Compuestos de heteroarilo biciclicos como inhibidores de pde10 PE20071116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75645006P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
PE20071116A1 true PE20071116A1 (es) 2007-11-17

Family

ID=38131538

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000001A PE20071116A1 (es) 2006-01-05 2007-01-03 Compuestos de heteroarilo biciclicos como inhibidores de pde10

Country Status (10)

Country Link
US (1) US20070155779A1 (es)
EP (1) EP1979343A2 (es)
JP (1) JP2009522346A (es)
AR (1) AR058919A1 (es)
CA (1) CA2636264A1 (es)
NL (1) NL2000397C2 (es)
PE (1) PE20071116A1 (es)
TW (1) TW200736246A (es)
UY (1) UY30080A1 (es)
WO (1) WO2007077490A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
AU2009262241B2 (en) * 2008-06-25 2014-05-22 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
EP2330906A4 (en) * 2008-08-15 2014-07-09 Univ Louisville Res Found CONNECTIONS, THEIR SYNTHESIS AND ITS USES
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
US8637500B2 (en) 2008-12-17 2014-01-28 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
CN105125547A (zh) * 2009-05-07 2015-12-09 费瑞姆医药有限公司 苯氧基甲基杂环化合物
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
EP2493308A4 (en) * 2009-10-30 2013-05-15 Merck Sharp & Dohme ARYLAMINOPYRIDIN PDE10 INHIBITORS
JP5778164B2 (ja) * 2009-10-30 2015-09-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap 放射標識pde10リガンド
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
EP2687529B1 (en) * 2011-03-16 2016-07-13 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
EP2714041B1 (en) * 2011-05-24 2016-10-19 Merck Sharp & Dohme Corp. Aryloxymethyl cyclopropane derivatives as pde10 inhibitors
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
PH12014500424A1 (en) * 2011-08-25 2016-08-03 Merck Sharp & Dohme Llc Pyrimidine pde10 inhibitors
UA108711C2 (uk) * 2011-09-19 2015-05-25 Ф. Хоффманн-Ля Рош Аг Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
RU2014123352A (ru) 2011-11-09 2015-12-20 Эббви Дойчланд Гмбх Унд Ко. Кг Гетероциклические карбоксамиды, полезные в качестве ингибиторов фосфодиэстеразы типа 10а
US9138494B2 (en) * 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
US9309232B2 (en) * 2012-04-24 2016-04-12 Board Of Trustees Of Northern Illinois University Synthesis of novel inhibitors of isoprenoid biosynthesis
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
WO2013163244A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
JP6101343B2 (ja) 2012-04-26 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 血小板凝集を治療するためのプロテアーゼ活性化受容体4(par4)阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2895489B1 (en) 2012-09-17 2017-10-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CA2902655A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
PL3055315T3 (pl) * 2013-10-11 2018-12-31 F. Hoffmann-La Roche Ag Tiazolopirymidynony jako modulatory aktywności receptora nmda
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
EP3856185A1 (en) 2018-09-28 2021-08-04 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
GB202110990D0 (en) * 2021-07-30 2021-09-15 Benevolentai Cambridge Ltd Organic compound and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US5843958A (en) * 1996-11-27 1998-12-01 Ortho Pharmaceutical Corporation Arylpyrazoles as leukotriene inhibitors
BRPI0511854A (pt) * 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
JP4302762B2 (ja) * 2005-01-07 2009-07-29 ファイザー・プロダクツ・インク 複素環式芳香族キノリン化合物およびpde10阻害剤としてのその使用

Also Published As

Publication number Publication date
NL2000397C2 (nl) 2007-10-30
JP2009522346A (ja) 2009-06-11
CA2636264A1 (en) 2007-07-12
US20070155779A1 (en) 2007-07-05
NL2000397A1 (nl) 2007-07-06
WO2007077490A3 (en) 2007-10-04
UY30080A1 (es) 2007-08-31
TW200736246A (en) 2007-10-01
AR058919A1 (es) 2008-03-05
EP1979343A2 (en) 2008-10-15
WO2007077490A2 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
PE20071116A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20081151A1 (es) Derivados de imidazol como activadores del receptor de adenosina a2a
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20140236A1 (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20081409A1 (es) Antagonistas del receptor de progesterona
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20081659A1 (es) Agonistas de gpcr
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20091527A1 (es) Derivados de piridazinona
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20070750A1 (es) COMPUESTOS DERIVADOS DE 1-AZA-BICICLONONANO COMO LIGANDOS COLINERGICOS DEL RECEPTOR DE ACETILCOLINA NICOTINICA (nAChR)
ATE400553T1 (de) 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
PE20091074A1 (es) Triazolotriazinas y triazolopirazinas y su uso
PE20120766A1 (es) Derivados de quinoxalina como inhibidores de tumores

Legal Events

Date Code Title Description
FC Refusal